Zelira Secures US$33M for HOPE 1 Autism Drug FDA Trial via ThirdGate Deal

Zelira Therapeutics (ASX: ZLD) has secured a transformative US$33 million institutional investment into its HOPE 1 Special Purpose Vehicle (SPV) from ThirdGate Capital. The capital raising values the SPV at a post-money valuation of US$65.96 million, with Zelira retaining a 39.70% equity stake valued at US$26.19 million. ThirdGate Capital will hold 50% of the SPV on a fully diluted basis, marking a significant validation of HOPE 1’s commercial potential and FDA approval pathway for treating Phelan-McDermid Syndrome, a rare form of Autism Spectrum Disorder.

ThirdGate Capital injects US$33M into Zelira’s HOPE 1 SPV

The definitive agreements signed between Zelira Therapeutics (ASX: ZLD) and TGC Biotechnology Fund, P.S. (ThirdGate Capital) will see US$32,981,075 (before costs) injected directly into the HOPE 1 SPV. This brings total equity issued by the SPV to US$36,558,000, positioning the entity to execute its FDA clinical trial programme without requiring further dilution of Zelira’s core shareholder base.

Under the finalised ownership structure, ThirdGate Capital holds 50.00%, Zelira retains 39.70%, The 2011 Forman Investment Trust holds 4.99%, Mr. Malik Majeed 0.44%, and a management incentive pool comprises 4.88%. The post-money SPV valuation of US$65.96 million reflects institutional confidence in HOPE 1’s regulatory and commercial prospects.

“This transformative Fundraising directly into the HOPE 1 SPV represents a compelling endorsement of our vision, our science, and the significant potential of HOPE 1. We welcome ThirdGate Capital as our partner and its recognition of what we have always believed: that HOPE 1 stands to revolutionise the treatment landscape for individuals living with autism, including rare and underserved forms, starting with Phelan-McDermid Syndrome. The Fundraising provides the SPV with sufficient capital to complete its accelerated regulatory pathway strategy utilising the United States’ FDA 505(b)(2) pathway. We are energised by the path forward and remain committed to delivering real solutions for autism patients, families and physicians/healthcare professionals who treat autism, while ensuring value for our shareholders,” said Dr Oludare Odumosu, Chief Executive Officer.

Zelira contributed intellectual property, real-world patient data, and the HOPE 1 product formulation in exchange for its equity position. Cash investors collectively funded US$36.56 million for a combined 55.42% stake, demonstrating significant institutional appetite for the asset.

“We are excited to partner with Zelira on this transformative journey to bring HOPE 1 through the FDA approval process. The compelling real-world patient data, combined with the clear regulatory pathway established through the Pre-IND meeting, gives us confidence in HOPE 1’s potential to address a significant unmet need for patients with Phelan-McDermid Syndrome and autism spectrum disorder,” said Cynthia Parrish, Senior Partner of ThirdGate Capital.

What is Phelan-McDermid Syndrome and why is HOPE 1 significant?

Phelan-McDermid Syndrome (PMS) is a genetically determined rare subset of Autism Spectrum Disorder caused by a deletion or mutation of the SHANK3 gene. The condition manifests with developmental delays, intellectual disability, autism-like behaviours, and communication challenges. Because PMS is genetically defined and affects a limited patient population, it qualifies as a rare disease under FDA guidelines.

The FDA confirmed in Q2 2024 that PMS with comorbidity with Autism is appropriate for study under Zelira’s proposed clinical plan design. This positions HOPE 1 to seek Orphan Drug Designation, which confers significant regulatory and commercial advantages.

Key characteristics of Phelan-McDermid Syndrome:

• Genetic deletion affecting SHANK3 gene
• Rare disease classification under FDA criteria
• Autism spectrum disorder comorbidity
• Limited existing treatment options

Orphan Drug Designation benefits:

• 7-year data exclusivity running concurrent with HOPE 1 patents
• Regulatory fee waivers and tax credits
• Accelerated review pathways
• Premium pricing potential due to unmet medical need

The Orphan Drug framework provides HOPE 1 with extended commercial protection beyond standard patent expiry, creating a longer revenue runway for the SPV and Zelira stakeholders.

How will the US$33M funding accelerate HOPE 1 FDA approval?

The capital injection fully funds HOPE 1’s FDA approval pathway via the 505(b)(2) accelerated regulatory route. This pathway allows the SPV to reference existing safety data while demonstrating HOPE 1’s specific efficacy for PMS, reducing clinical development timelines and costs compared to traditional New Drug Application (NDA) processes.

In Q2 2024, Zelira completed a Pre-IND (Investigational New Drug) meeting with the FDA, which provided clarity on the development pathway. The agency endorsed Zelira’s IND-enabling plans, confirming a clear runway to file an IND and initiate the formal FDA first-in-human clinical trial. This represented a critical de-risking event for the programme.

The SPV has allocated funding across two phases:

• Phase 1/2 clinical trial budget: US$17.69 million
• Phase 3 clinical trial budget: US$14.07 million

The SPV has appointed iNGENū CRO Pty Ltd as its exclusive Contract Research Organisation to lead clinical validation and regulatory registration. This partnership ensures specialised expertise in navigating FDA requirements for rare disease indications.

“I am thrilled to build on our relationship with the ThirdGate Capital Team to get HOPE through the FDA process in the most efficient and expeditious manner. We are grateful for ThirdGate Capital’s funding and investment and that of The 2011 Forman Investment Trust and Mr. Malik Majeed, who were our first institutional/Family Office investors into the SPV. Their initial funding was crucial in getting the SPV to the inflection point at which we were able to attract ThirdGate Capital’s interest and transformative funding investment. With this funding secured, we are now laser focused on progressing our HOPE FDA clinical program,” said Osagie Imasogie, Executive Chairman of the SPV.

The fully funded pathway eliminates execution risk associated with future capital raises and allows management to focus exclusively on regulatory milestones.

What does the ThirdGate Capital investment mean for Zelira shareholders?

SPV structure protects Zelira’s core assets

Zelira’s strategic use of an SPV structure isolates HOPE 1 development costs and equity dilution from the parent company’s balance sheet. The SPV arrangement means cash investors funded US$36.56 million directly into the SPV entity, not Zelira Therapeutics Ltd. As a result, Zelira’s existing shareholders experience no immediate dilution to their core holdings.

Zelira contributed intellectual property, real-world patient data, and the HOPE 1 product formulation in exchange for a 39.70% equity stake in the SPV, currently valued at US$26.19 million. This represents a material asset on Zelira’s balance sheet without requiring cash outlay.

Critically, Zelira retains 100% ownership of all non-HOPE assets, including ZENIVOL (insomnia treatment being commercialised in Germany), RAF FIVE (OTC acne products), SprinJeneCBD oral care line, and its chronic pain pipeline. These revenue-generating assets continue to operate independently of the SPV structure.

Zelira and ThirdGate Capital have confirmed no present intention to spin out or separately list the SPV on any exchange. The entity will operate as part of Zelira’s managed portfolio, providing upside exposure without operational distraction.

Governance and strategic oversight

The SPV board comprises five directors: three designated by ThirdGate Capital and two by Zelira. Marlon Thomas (Founder and Chief Investment Officer of ThirdGate) and Cynthia Parrish have been appointed as ThirdGate’s initial directors, with one additional director to be named subsequently. Osagie Imasogie serves as Executive Chairman, with Dr Donna Gentile O’Donnell appointed as Zelira’s second director.

The management incentive pool of 4.88% is split between two vesting mechanisms:

1. FDA Approval Vesting (2.44%, or 321,895 units): Vests upon receipt of final FDA approval letter, directly aligning management interests with regulatory success.

2. Time-Based Vesting (2.44%, or 321,895 units): Vests over a three-year period, encouraging long-term commitment and operational continuity.

All management team members and their respective allocations require approval by ThirdGate prior to grant, ensuring institutional oversight of incentive allocation.

The board structure balances institutional capital expertise (ThirdGate’s three seats) with Zelira’s scientific and regulatory knowledge (two seats), while management incentives are strictly tied to FDA milestones and sustained execution.

Strategic roadmap and near-term milestones

The SPV’s immediate priorities centre on three regulatory and clinical execution milestones:

1. IND submission for HOPE 1 to the FDA, aligned with guidance provided during the Pre-IND meeting in Q2 2024.

2. Initiation of Phase 1 clinical trial, marking the first-ever formal dosing of HOPE 1 under FDA oversight.

3. Filing for Orphan Drug Designation, leveraging PMS’s rare disease status to unlock regulatory incentives and commercial exclusivity.

Each milestone represents a material re-rating catalyst for the SPV and, by extension, Zelira’s 39.70% equity interest. The Phase 1 trial will provide critical safety and pharmacokinetic data, whilst Orphan Drug Designation confers 7-year data exclusivity concurrent with HOPE 1’s patent protection.

Beyond HOPE 1, Zelira continues to generate revenue from multiple commercial channels:

• HOPE brand: Currently commercialised in Australia, Washington, D.C., Pennsylvania, and Louisiana.
• ZENIVOL: Expanding into Germany via commercialisation partner Adjupharm GmbH following BfArM approval.
• SprinJeneCBD oral care line: Generating revenue in the US market.
• RAF FIVE acne treatment products: Five OTC formulations incorporating cannabidiol (CBD).

This diversified revenue base provides Zelira with operational cash flow independent of the SPV’s clinical trial timeline, reducing reliance on equity markets to fund core operations.

Investment Implications:

The ThirdGate Capital partnership validates HOPE 1’s commercial potential whilst insulating Zelira shareholders from clinical trial execution risk. The SPV structure provides asymmetric upside exposure, with Zelira retaining a US$26.19 million equity stake without capital contribution, whilst preserving 100% ownership of revenue-generating assets outside the SPV.

Stay ahead in Biotech with Big News Blasts

Subscribe for FREE to the Big News Blasts, the trusted service of over 20,000 investors delivering breaking developments and in-depth analysis on biotech, healthcare, and other non-resource ASX sectors. To receive timely updates like this Zelira Therapeutics capital raise and regulatory progress, simply click the “Free Alerts” button in the menu and join the growing community of informed subscribers on StockWire X.